DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksSchließen
Referenz
A randomized, double-blind, multi-center phase III study of brivanib plus best supportive care (BSC) versus placebo plus BSC in Asian subjects with advanced hepatocellular carcinoma (HCC) who have failed or are intolerant to sorafenib (BRISK-APS).
Available at:
http://clinicaltrials.gov/ct2/show/NCT01108705 . Accessed January 11, 2012
Für die Inhalte der Internetseiten anderer Anbieter übernehmen wir keine Verantwortung.